June 11, 2020 / 12:56 AM / a month ago

BRIEF-U.S. FDA Approves Opdivo (Nivolumab) For The Treatment Of Patients With Advanced Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine- And Platinum-Based Chemotherapy

June 10 (Reuters) - Bristol-Myers Squibb Co:

* U.S. FOOD AND DRUG ADMINISTRATION APPROVES OPDIVO® (NIVOLUMAB) FOR THE TREATMENT OF PATIENTS WITH ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) AFTER PRIOR FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY

* APPLICATION WAS GRANTED PRIORITY REVIEW DESIGNATION BY FDA, AND APPROVAL IS BASED ON PHASE 3 ATTRACTION-3 TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below